Want to see VKTX full AI Analyst Report?
Total Valuation
Viking Therapeutics has a market cap or net worth of $3.70B. The enterprise value is $4.04K.
Market Cap$3.70B
Enterprise Value$4.04K
Share Statistics
Viking Therapeutics has 116,652,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding116,652,940
Owned by Insiders2.96%
Owned by Institutions1.33%
Financial Efficiency
Viking Therapeutics’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -61.54%.
Return on Equity (ROE)-0.56
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-61.54%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee0.00
Profits Per Employee-6.10M
Employee Count59
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Viking Therapeutics is ―. Viking Therapeutics’s PEG ratio is -0.05.
PE Ratio―
PS Ratio0.00
PB Ratio6.20
Price to Fair Value6.20
Price to FCF-14.22
Price to Operating Cash Flow-8.79
PEG Ratio-0.05
Income Statement
In the last 12 months, Viking Therapeutics had revenue of 0.00 and earned -359.64M in profits. Earnings per share was -3.19.
Revenue0.00
Gross Profit-431.00K
Operating Income-393.34M
Pretax Income-359.64M
Net Income-359.64M
EBITDA-359.15M
Earnings Per Share (EPS)-3.19
Cash Flow
In the last 12 months, operating cash flow was -418.44M and capital expenditures 0.00, giving a free cash flow of -418.44M billion.
Operating Cash Flow-418.44M
Free Cash Flow-418.44M
Free Cash Flow per Share-3.59
Dividends & Yields
Viking Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.24
52-Week Price Change-6.59%
50-Day Moving Average34.01
200-Day Moving Average33.80
Relative Strength Index (RSI)44.99
Average Volume (3m)2.52M
Important Dates
Viking Therapeutics upcoming earnings date is Oct 28, 2026, After Close (Confirmed).
Last Earnings DateJul 29, 2026
Next Earnings DateOct 28, 2026
Ex-Dividend Date―
Financial Position
Viking Therapeutics as a current ratio of 9.33, with Debt / Equity ratio of 1.00%
Current Ratio9.33
Quick Ratio9.33
Debt to Market Cap0.00
Net Debt to EBITDA0.46
Interest Coverage Ratio-7.02K
Taxes
In the past 12 months, Viking Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Viking Therapeutics EV to EBITDA ratio is -10.57, with an EV/FCF ratio of -13.63.
EV to Sales0.00
EV to EBITDA-10.57
EV to Free Cash Flow-13.63
EV to Operating Cash Flow-13.63
Balance Sheet
Viking Therapeutics has $501.66M in cash and marketable securities with $4.09M in debt, giving a net cash position of $497.58M billion.
Cash & Marketable Securities$501.66M
Total Debt$4.09M
Net Cash$497.58M
Net Cash Per Share$4.27
Tangible Book Value Per Share$5.67
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Viking Therapeutics is $92.08, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$92.08
Price Target Upside164.68% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast―
EPS Growth Forecast-203.77%